Objective To examine the unique and congruent findings between multiple raters in a
genome-wide association study (GWAS) in the context of understanding individual …

Clinical symptom response to antipsychotic medications is highly variable. Genome-wide
association studies (GWAS) provide a 'hypothesis-free'method of interrogating the genome …

Objective Clinical response to the atypical antipsychotic paliperidone is known to vary
among schizophrenic patients. We carried out a genome-wide association study to identify …

Objective: Pharmacogenomic studies of antipsychotics have typically examined effects of
individual polymorphisms. By contrast, polygenic risk scores (PRSs) derived from genome …

Insight in schizophrenia is clinically important as it is associated with several adverse
outcomes. Genetic contributions to insight are unknown. We examined genetic contributions …

Background Although antipsychotics are integral to the treatment of schizophrenia, drug
efficacy varies between patients. Although it has been shown that antipsychotic treatment …

Antipsychotic treatment response is highly heterogeneous and unpredictable in terms of
both efficacy and side effects. A combination of factors influences treatment outcome …

Background Genome-wide association studies (GWAS) have significantly contributed to the
association of many clinical conditions and phenotypic characteristics with genomic variants …

Schizophrenia is an often devastating neuropsychiatric illness. Understanding the genetic
variation affecting response to antipsychotics is important to develop novel diagnostic tests …

Background Antipsychotic drugs improve schizophrenia symptoms and reduce the
frequency of relapse, but treatment response is highly variable. Little is known about the …